Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 0 | 0 | 0 | 0 | 688 |
| Gross Profit | N/A | N/A | 0 | N/A | 688 |
| Operating Expenses | 44,147 | 47,774 | 45,914 | 18,337 | 159,934 |
| Operating Income | -44,147 | -47,774 | -45,914 | -18,337 | -159,246 |
| Other Income | 5,310 | 3,949 | -17,266 | -21,767 | -57,828 |
| Pre-tax Income | -38,837 | -43,825 | -63,180 | -40,104 | -217,074 |
| Income Tax | N/A | 32 | 14 | 3 | -7 |
| Net Income Continuous | -38,837 | -43,857 | -63,194 | -40,107 | -217,067 |
| Net Income | $-38,837 | $-43,857 | $-63,180 | $-40,107 | $-217,081 |
| EPS Basic Total Ops | -0.59 | -0.72 | -3.23 | -0.86 | -40.14 |
| EPS Basic Continuous Ops | -0.86 | -1.20 | 21.89 | -9.34 | -56.79 |
| EPS Diluted Total Ops | -0.59 | -0.72 | -3.23 | -0.86 | -40.14 |
| EPS Diluted Continuous Ops | -0.86 | -1.20 | 21.89 | -9.34 | -56.79 |
| EPS Diluted Before Non-Recurring Items | -0.86 | -1.20 | -2.28 | N/A | N/A |
| EBITDA(a) | $-44,147 | $-47,774 | $-48,232 | $-18,337 | $-158,830 |